Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Sponsor
Peking Union Medical College Hospital
Study ID
NCT04973904
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Toripalimab — DRUG
    IV infusion
  • Paclitaxel — DRUG
    IV infusion
  • Cisplatin — DRUG
    IV infusion
  • Bevacizumab — DRUG
    IV infusion

Study Details

This is a single-arm, multicenter, phase II study to investigate efficacy and safety of Toripalimab combined with chemotherapy (paclitaxel and cisplatin) and Bevacizumab as first-line treatment in patients with recurrent, refractory and metastatic cervical cancer

Key Dates

First listed
Jul 22, 2021
Start date
Aug 1, 2021
Status verified
Jul 2021
Primary completion
Dec 1, 2022
Completion
Dec 1, 2023

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PD-1+Paclitaxel+Cisplatin+Bevacizumab
    Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) Paclitaxel 175mg/m2 IV every 3 weeks (Q3W) Cisplatin 50mg/m2 (Q3W) Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)

Primary Outcome Measure

Overall response rate [ Time Frame: 1 year ]

Central Contacts

Related Studies